Immunome Inc

NAS:IMNMHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$16.77+1.82%At closeAt close · Tue 20 Oct · ≈ AED 61.59 · Market cap $1.9B · Next earnings Thu 5 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	—	—	—	100.0%	100.0%	57.4%	—	—
Operating margin	—	—	—	−781.4%	−3,382.4%	−3,084.8%	−3,084.8%	+0.0 pts
Net margin	—	—	—	−761.9%	−3,240.4%	−3,060.0%	−3,060.0%	+0.0 pts
EBITDA margin	—	—	—	−199.7%	−1,674.1%	−3,017.4%	—	—
Return on equity	−43.1%	−51.3%	−221.6%	−89.1%	−161.7%	−33.5%	−33.5%	+0.0 pts
Return on assets	−40.1%	−42.7%	−153.4%	−71.9%	−121.9%	−31.1%	−31.1%	+0.0 pts
Return on capital employed	−29.6%	−52.3%	−220.8%	−86.4%	−164.5%	−33.5%	—	—
Debt / equity	0.0×	0.0×	0.0×	0.0×	0.0×	0.0×	0.0×	+0.0%
Debt / assets	1.4%	0.5%	1.2%	1.1%	2.0%	0.6%	—	—
Interest coverage	−322.7×	−2,520.4×	−7,380.2×	0.0×	0.0×	0.0×	—	—
Current ratio	14.1×	5.8×	3.1×	6.6×	4.1×	14.7×	14.7×	+0.0%
Quick ratio	14.1×	5.8×	3.1×	6.6×	4.1×	14.7×	—	—
Cash ratio	13.1×	5.1×	2.8×	4.5×	2.6×	14.5×	14.5×	+0.0%
Asset turnover	0.0×	0.0×	0.0×	0.1×	0.0×	0.0×	—	—
Receivables turnover	0.0×	0.0×	0.0×	48.5×	—	—	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.